VolitionRx Secures NYSE Compliance with Action Plan Approval
On April 22, 2026, VolitionRx Limited, a leading player in the field of epigenetics, made a significant stride in maintaining its public listing on the NYSE American. The company announced that the NYSE American accepted its compliance plan, crucial for continuing its operations on the exchange. This development comes in the wake of a notice received on February 6, 2026, highlighting Volition's lack of compliance with the exchange's continued listing standards due to insufficient stockholders' equity.
According to the provisions set within the NYSE American Company Guide, a firm must maintain a minimum stockholder's equity of $2 million if it has recorded operational losses in two of its previous three fiscal years, $4 million in three of its past four years, and $6 million across five years. Volition was unable to meet these metrics and consequently was alerted about its non-compliance status. Facing this challenge, VolitionRx was required to develop and submit a detailed plan by March 8, 2026, articulating how it intends to address these deficiencies by August 6, 2027.
Upon timely submission of its compliance strategy, VolitionRx received a positive response from the NYSE, granting the company a structured timeline to rectify its financial standings in line with the necessary guidelines. The acceptance of their plan provides a critical lifeline, giving the company until August 6, 2027, to achieve compliance, all while it remains under periodic scrutiny from the NYSE.
During this plan period, VolitionRx will diligently work towards regaining compliance with the specified sections laid out in the guidelines to secure its future on the exchange. The company is committed to implementing actions that will help rebuild stockholders' equity in the required time frame, recognizing that the potential consequences of falling short—such as delisting—would considerably impact their market presence and operational capability.
It is important to emphasize that the reception of the acceptance letter does not disrupt their current operations or the listing and trading of Volition's common stock, which will continue on the NYSE American, contingent upon adherence to other requirements. Hence, the immediate aftermath sees no drastic changes for its stakeholders or market activities.
VolitionRx is profoundly focused on revolutionizing healthcare through its innovation in epigenetics. The company’s mission revolves around improving life outcomes for individuals suffering from severe medical conditions through early disease detection and continuous monitoring via groundbreaking blood tests.
With headquarters firmly in Henderson, Nevada, and operational bases in Belgium, as well as offices in both London and the United States, VolitionRx showcases its multinational outreach. Its ambition to deliver efficient and cost-effective diagnostic solutions emphasizes the profound importance of timely disease intervention in enhancing survival rates and overall quality of life.
As time unfolds, the company's next steps will be instrumental in determining its trajectory. The challenge lies not only in adhering to the compliance framework set by the NYSE but also in sustaining its innovative edge in the healthcare sector through continuous research and development. VolitionRx's progress in these realms will be watched closely by investors, stakeholders, and the healthcare community alike.
In sum, VolitionRx Limited's journey towards compliance sets the stage for the next chapter in its endeavors, making it a noteworthy subject as the company navigates its path towards stability on the NYSE American amidst the evolving landscape of epigenetic research and testing.
According to the provisions set within the NYSE American Company Guide, a firm must maintain a minimum stockholder's equity of $2 million if it has recorded operational losses in two of its previous three fiscal years, $4 million in three of its past four years, and $6 million across five years. Volition was unable to meet these metrics and consequently was alerted about its non-compliance status. Facing this challenge, VolitionRx was required to develop and submit a detailed plan by March 8, 2026, articulating how it intends to address these deficiencies by August 6, 2027.
Upon timely submission of its compliance strategy, VolitionRx received a positive response from the NYSE, granting the company a structured timeline to rectify its financial standings in line with the necessary guidelines. The acceptance of their plan provides a critical lifeline, giving the company until August 6, 2027, to achieve compliance, all while it remains under periodic scrutiny from the NYSE.
During this plan period, VolitionRx will diligently work towards regaining compliance with the specified sections laid out in the guidelines to secure its future on the exchange. The company is committed to implementing actions that will help rebuild stockholders' equity in the required time frame, recognizing that the potential consequences of falling short—such as delisting—would considerably impact their market presence and operational capability.
It is important to emphasize that the reception of the acceptance letter does not disrupt their current operations or the listing and trading of Volition's common stock, which will continue on the NYSE American, contingent upon adherence to other requirements. Hence, the immediate aftermath sees no drastic changes for its stakeholders or market activities.
VolitionRx is profoundly focused on revolutionizing healthcare through its innovation in epigenetics. The company’s mission revolves around improving life outcomes for individuals suffering from severe medical conditions through early disease detection and continuous monitoring via groundbreaking blood tests.
With headquarters firmly in Henderson, Nevada, and operational bases in Belgium, as well as offices in both London and the United States, VolitionRx showcases its multinational outreach. Its ambition to deliver efficient and cost-effective diagnostic solutions emphasizes the profound importance of timely disease intervention in enhancing survival rates and overall quality of life.
As time unfolds, the company's next steps will be instrumental in determining its trajectory. The challenge lies not only in adhering to the compliance framework set by the NYSE but also in sustaining its innovative edge in the healthcare sector through continuous research and development. VolitionRx's progress in these realms will be watched closely by investors, stakeholders, and the healthcare community alike.
In sum, VolitionRx Limited's journey towards compliance sets the stage for the next chapter in its endeavors, making it a noteworthy subject as the company navigates its path towards stability on the NYSE American amidst the evolving landscape of epigenetic research and testing.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.